Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Filter our case studies by categories, selecting amongst our broad range of solutions.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
Accelerating clinical trial programs in dermatology
The client tasked ICON plc with managing six phase 3 clinical trials, with overlapping timelines, to further evaluate this
drug in patients with AD.
drug in patients with AD.
Achondroplasia
The client was conducting a a pharmaco-epidemiologic study to characterise the impacts and burden of Achondroplasia across the lifespan.
Overcoming recruitment challenges
ICON successfully overcame site activation and patient recruitment challenges in an early Parkinson’s disease (PD) study.
In-Home Services: Trial continuity during COVID-19
A biopharmaceutical company was running a global 4-study program evaluating the long-term safety and effectiveness of a study drug in adult patients with a rare, inherited disease impacting the kidneys and other vital organs.
Flexible and meticulous management
A large pharma sponsor was conducting a Phase 2/3 randomised, placebo-controlled COVID-19 vaccine study. Facing labour and supply shortages, as well as unprecedented safety challenges due to the ongoing pandemic, the sponsor contracted Accellacare to support their staffing, enrollment, and logistics across seven US sites.
.jpg?crop=yes&w=1920&h=1010&a=0,135&itok=Ez1bgfiA "Nurse-in-scrubs-child-engagement-(2)"){kind=icon}
In-Home Services: Rescue: accelerated patient recruitment
A biotechnology company was attempting to recruit 40 paediatric patients in a US phase II oncology study.
In-Home Services: Patient satisfaction levels in rare disease
Large pharmaceutical company was running a phase II study to assess the efficacy of a study drug in paediatric patients with a rare degenerative genetic disorder. The study required weekly infusions for more than 50 patients in the UK.
Overcoming challenges in non small cell lung carcinoma rescue study
A mid sized Pharma organisation was conducting a Phase Ib trial with plans to enroll 188 Non Small Cell Lung Carcinoma patients in Cohort B.
Patient insights & strategy
We developed and facilitated a series of Patient Partner Workshops™. Patients engaged in a variety of unique activities designed to stimulate open, honest dialogue among the group.
Agile operations drive enrollment in COVID-19 treatment studies
A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.
genetic seizure disorder in children.
Overcoming recruitment challenges
ICON partnered with a drug development sponsor to conduct a multicenter, randomised, double-blind, placebo-controlled,
proof of concept study of the efficacy and safety of a treatment for patients with fibromyalgia.
proof of concept study of the efficacy and safety of a treatment for patients with fibromyalgia.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.